GORECKI, Lukas, Anna MISIACHNA, Jiří DAMBORSKÝ, Rafael DOLEZAL, Jan KORABECNY, Lada CEJKOVA, Kristina HAKENOVA, Marketa CHVOJKOVA, Jana KARASOVA ZDAROVA, Lukas PRCHAL, Martin NOVAK, Marharyta KOLCHEVA, Stepan KORTUS, Karel VALES, Martin HORAK and Ondřej SOUKUP. Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-D-Aspartate receptors. European Journal of Medicinal Chemistry. PARIS: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, vol. 219, July 2021, p. 1-16. ISSN 0223-5234. Available from: https://dx.doi.org/10.1016/j.ejmech.2021.113434.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-D-Aspartate receptors
Authors GORECKI, Lukas (203 Czech Republic), Anna MISIACHNA (203 Czech Republic), Jiří DAMBORSKÝ (203 Czech Republic, guarantor, belonging to the institution), Rafael DOLEZAL (203 Czech Republic), Jan KORABECNY (203 Czech Republic), Lada CEJKOVA (203 Czech Republic), Kristina HAKENOVA (203 Czech Republic), Marketa CHVOJKOVA (203 Czech Republic), Jana KARASOVA ZDAROVA (203 Czech Republic), Lukas PRCHAL (203 Czech Republic), Martin NOVAK (203 Czech Republic), Marharyta KOLCHEVA (203 Czech Republic), Stepan KORTUS (203 Czech Republic), Karel VALES (203 Czech Republic), Martin HORAK (203 Czech Republic) and Ondřej SOUKUP (203 Czech Republic).
Edition European Journal of Medicinal Chemistry, PARIS, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, 0223-5234.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30107 Medicinal chemistry
Country of publisher France
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.088
RIV identification code RIV/00216224:14310/21:00122286
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1016/j.ejmech.2021.113434
UT WoS 000646945500020
Keywords in English QSAR; Acetylcholinesterase; Electrophysiology; Glutamate receptor; Ion channel; Pharmacology; in vivo; Tacrine
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michaela Hylsová, Ph.D., učo 211937. Changed: 16/2/2023 12:42.
Abstract
Tacrine is a classic drug whose efficacy against neurodegenerative diseases is still shrouded in mystery. It seems that besides its inhibitory effect on cholinesterases, the clinical benefit is co-determined by NMDAR-antagonizing activity. Our previous data showed that the direct inhibitory effect of tacrine, as well as its 7-methoxy derivative (7-MEOTA), is ensured via a "foot-in-the-door" open-channel blockage, and that interestingly both tacrine and 7-MEOTA are slightly more potent at the GluN1/GluN2A receptors when compared with the GluN1/GluN2B receptors. Here, we report that in a series of 30 novel tacrine derivatives, designed for assessment of structure-activity relationship, blocking efficacy differs among different compounds and receptors using electrophysiology with HEK293 cells expressing the defined types of NMDARs. Selected compounds (4 and 5) potently inhibited both GluN1/GluN2A and GluN1/GluN2B receptors; other compounds (7 and 23) more effectively inhibited the GluN1/GluN2B receptors; or the GluN1/GluN2A receptors (21 and 28). QSAR study revealed statistically significant model for the data obtained for inhibition of GluN1/Glu2B at -60 mV expressed as IC50 values, and for relative inhibition of GluN1/Glu2A at +40 mV caused by a concentration of 100 mu M. The models can be utilized for a ligand-based virtual screening to detect potential candidates for inhibition of GluN1/Glu2A and/or GluN1/Glu2B subtypes. Using in vivo experiments in rats we observed that unlike MK-801, the tested novel compounds did not induce hyperlocomotion in open field, and also did not impair prepulse inhibition of startle response, suggesting minimal induction of psychotomimetic side effects. We conclude that tacrine derivatives are promising compounds since they are centrally available subtype-specific inhibitors of the NMDARs without detrimental behavioral side-effects.
PrintDisplayed: 13/7/2024 13:06